Sodium-glucose cotransporter 2 (SGLT2) inhibitors

Journal articles and book chapters

06-15-2019 | Bone health | Article

Analysis of fractures in patients with type 2 diabetes treated with empagliflozin in pooled data from placebo-controlled trials and a head-to-head study versus glimepiride

Kohler S et al. Diabetes Care 2018: dc171525. doi: 10.2337/dc17-1525

11-08-2018 | Cardiovascular disorders | Review | Article

The evolving role of the cardiologist in the management of type 2 diabetes

Chilton RJ et al. Curr Diab Rep 2018; 18: 144. doi: 10.1007/s11892-018-1114-1

10-08-2018 | Dapagliflozin | Article

Impact of dapagliflozin on left ventricular diastolic function of patients with type 2 diabetic mellitus with chronic heart failure

Soga F et al. Cardiovasc Diabetol 2018; 17: 132. doi: 10.1186/s12933-018-0775-z

09-12-2018 | SGLT2 inhibitors | Article

Comparative risk of genital infections associated with SGLT2 inhibitors: A real‐world retrospective cohort study

Dave CV et al. Diabetes Obes Metab 2018. doi: 10.1111/dom.13531

09-05-2018 | Older adults | Review | Article

Diabetes treatment in the elderly: Incorporating geriatrics, technology, and functional medicine

Valencia WM et al. Curr Diab Rep 2018; 18: 95. doi: 10.1007/s11892-018-1052-y

08-26-2018 | Oral combination medications | Article

Mechanistic insights from sequential combination therapy with an SGLT2 inhibitor and DPP‐IV inhibitor: Results from the CANARIS trial using canagliflozin and teneligliptin

Okahata S et al. Diabetes Obes Metab 2018. doi: 10.1111/dom.13505

08-23-2018 | Dapagliflozin | Article

Effectiveness of dapagliflozin versus comparators on renal endpoints in the real world: A multicenter retrospective study

Fadini GP et al. Diabetes Obes Metab 2018. doi: 10.1111/dom.13508

08-23-2018 | Empagliflozin | Article

Real‐world opportunity of empagliflozin to improve blood pressure control in African Americans with type 2 diabetes: An NCDR® “research‐to‐practice” project from the Diabetes Collaborative Registry (DCR)

Arnold SV et al. Diabetes Obes Metab 2018. doi: 10.1111/dom.13510

08-18-2018 | Medications | Article

Comparison of oral antidiabetic drugs as add-on treatments in patients with type 2 diabetes uncontrolled on metformin: A network meta-analysis

Qian D et al. Diabetes Ther 2018. doi: 10.1007/s13300-018-0482-5

08-17-2018 | Medications | Review | Article

Adjuvant pharmacotherapies to insulin for the treatment of type 1 diabetes

Tosur M, Redondo MJ, Lyons SK. Curr Diab Rep 2018; 18: 79. doi: 10.1007/s11892-018-1041-1

08-09-2018 | Sitagliptin | Article

Adverse drug events associated with sitagliptin versus canagliflozin for the treatment of patients with type 2 diabetes mellitus: A systematic comparison through a meta-analysis

Bundhun PK, Huang F. Diabetes Ther 2018. doi: 10.1007/s13300-018-0481-6

08-05-2018 | Exenatide | Article

Safety and efficacy of exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy: 52-week results of the DURATION-8 randomized controlled trial

Jabbour SA et al. Diabetes Care 2018: dc180680. doi: 10.2337/dc18-0680

07-23-2018 | SGLT2 inhibitors | Review | Article

SGLT2 inhibitors in type 2 diabetes management: Key evidence and implications for clinical practice

Wilding J et al. Diabetes Ther 2018. doi: 10.1007/s13300-018-0471-8

07-19-2018 | Dapagliflozin | Article

Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (the DEPICT-2 study): 24-week results from a randomized controlled trial

Methieu C et al. Diabetes Care 2018: dc180623. doi: 10.2337/dc18-0623

07-16-2018 | Ipragliflozin | Article

Efficacy and safety of ipragliflozin as add-on therapy to insulin in Japanese patients with type 2 diabetes mellitus (IOLITE): A 36-week, open-label extension of a 16-week, randomized, placebo-controlled, double-blind study

Ishihara H et al. Diabetol Int 2018. doi: 10.1007/s13340-018-0359-x

06-24-2018 | Sotagliflozin | Article

Sotagliflozin in combination with optimized insulin therapy in adults with type 1 diabetes: The North American inTandem1 study

Buse JB et al. Diabetes Care 2018. doi: 10.2337/dc18-0343

06-23-2018 | Cardiovascular outcomes | Review | Article

Cardiovascular outcome studies in type 2 diabetes: Comparison between SGLT2 inhibitors and GLP-1 receptor agonists

Scheen AJ. Diabetes Res Clin Prac 2018; 143: 88–100. doi: 10.1016/j.diabres.2018.06.008

06-23-2018 | Heart failure | Article

Association between sodium glucose co-transporter 2 inhibitors and a reduced risk of heart failure in patients with type 2 diabetes mellitus: A real-world nationwide population-based cohort study

Kim YG et al. Cardiovasc Diabetol 2018; 17: 91. doi: 10.1186/s12933-018-0737-5

06-22-2018 | Hypertension | Review | Article

The optimal blood pressure target in diabetes mellitus: A quest coming to an end?

Papadopoulou E et al. J Hum Hypertens 2018. doi: 10.1038/s41371-018-0079-5

06-21-2018 | Canagliflozin | Article

Canagliflozin and renal outcomes in type 2 diabetes: Results from the CANVAS program randomized clinical trials

Perkovic V et al. Lancet Diabetes Endocrinol 2018. doi: 10.1016/S2213-8587(18)30141-4